Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Sarcoma 2Rhabdomyosarcoma 2Medulloblastoma 2Uveal Melanoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Laryngeal Diseases 1Glioma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

tislelizumab 2tazemetostat 2belinostat 2spartalizumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1Temozolomide 1Sorafenib 1Rifampin 1Quality of Life 1Plicamycin 1Pemetrexed 1Patient Reported Outcome Measures 1PM 01183 1OSI 930 1Nivolumab 1Molecular Diagnostic Techniques 1LY2940680 1Itraconazole 1Irinotecan 1Immunotherapy, Adoptive 1Immunotherapy 1Imatinib Mesylate 1Fluorouracil 1Fluorodeoxyglucose F18 1Erlotinib Hydrochloride 1Drug Therapy 1Doxepin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × LY2940680 × Sarcoma × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡